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Purpose: To evaluate the accuracy of benign core biopsy of probably benign breast lesions 
(category 3) 2 cm or larger on the basis of excisional biopsy and long-term follow-up.
Methods: We retrospectively reviewed 146 category 3 lesions in 146 patients 2 cm or larger 
which were diagnosed as benign by ultrasound (US)-guided core biopsy. Patients were initially 
diagnosed as benign at core needle biopsy and then followed up with excisional biopsy (surgical 
excision, n=91; US-guided vacuum assisted excision, n=35) or breast ultrasonography (n=20).
Results: Of the 126 patients who underwent surgical excision or US-guided vacuum-assisted 
excision, 114 patients were diagnosed with benign lesions, 10 patients with borderline lesions 
(benign phyllodes tumor), and two patients with malignant phyllodes tumors. The probabilities of 
lesions being benign, borderline and malignant were 91.8% (134/146), 6.8% (10/146), and 1.4% 
(2/146), respectively. Of 13 patients who had growing masses on follow-up ultrasonography, three 
(23.1%) were non-benign (two benign phyllodes tumors and one malignant phyllodes tumor).
Conclusion: US-guided core needle biopsy of probably benign breast mass 2 cm or larger was 
accurate (98.6%) enough to rule out malignancy. But, it was difficult to rule out borderline 
lesions even when they were diagnosed as benign.
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Introduction
High resolution breast ultrasonography has been increasingly used because of its advantages in the 
detection, characterization and differentiation of lesions, with lesions being diagnosed as benign to 
malignant [1-3]. According to the Breast Imaging-Reporting and Data System (BI-RADS), category 
3, probably benign, on ultrasonography is defined as a solid mass with oval shape, circumscribed 
margin, parallel orientation, and no suspicious malignant features [4]. Short-interval follow-up is most 
often recommended for category 3 lesions because the probability of malignancy is low (<2%) and 
unnecessary breast biopsies of benign lesions, morbidity and medical costs can all be reduced with 
just follow-up.Benign core biopsy of probably benign breast mass
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Even though palpable or non-palpable probably benign lesions 
have a short-interval imaging follow-up recommended rather than 
biopsy, the triple test (physical examination, mammogram, and fine-
needle aspiration) or modified triple test (physical examination, 
mammography and/or ultrasonography, and fine-needle aspiration 
and/or biopsy) has been used to evaluate palpable lesions in 
clinical practice [5]. However, there is relatively little research on the 
accuracy of core needle biopsy for palpable lesions [6-9] and, in 
particular, on its ability to identify borderline lesions.
The purpose of our study was to investigate the accuracy of 
benign core needle biopsy of probably benign breast masses 2 cm 
or larger on the basis of excisional biopsy and long-term follow-up.
Materials and Methods
Institutional Review Board approval was obtained for this 
retrospective study.
Study Population
We retrospectively reviewed lesions assessed as category 3 probably 
benign according to BI-RADS from October 2001 to December 2009. 
Among 207 patients who were initially assessed with category 3 
solid masses 2 cm or larger on ultrasonography with US-guided 
core needle biopsy (US-CNB), 199 patients were diagnosed with 
benign lesions and the remaining 8 patients were diagnosed with 
malignant (n=1, invasive ductal carcinoma) or borderline lesions 
(n=7; 6 phyllodes tumors, 1 intraductal papilloma). Among 199 
patients with benign biopsies, 53 patients were excluded because 
they were lost to follow-up less that was than 2 years. Finally, 146 
masses in 146 patients were included in this study (Fig. 1).
Pathologic results of US-CNB were as follows: fibroadenoma 
(n=64), fibrocystic change (n=25), stromal fibrosis (n=18), 
fibroadenomatous hyperplasia (n=19), adenosis (n=4), benign 
breast tissue such as fibroadipose tissue (n=5), duct ectasia (n=4), 
apocrine metaplasia (n=1), ductal epithelial hyperplasia (n=1), 
granular cell tumor (n=1), lactating adenoma (n=1), lactating 
adenosis (n=1), palisading granuloma (n=1), and sclerosing 
adenosis (n=1).
Ultrasonography and US-guided Core Needle Biopsy
Ultrasonography was performed using a 5-10 MHz or 5-12 MHz 
linear array transducer (HDI 3000 or 5000, Advanced Technology 
Laboratories, Philips Medical Systems, Bothell, WA, USA; Logic 
9, GE Healthcare, Milwaukee, WI, USA; iU22, Philips Healthcare, 
Bothell) by one of nine dedicated breast imaging radiologists with 
1 to 11 years of experience. All ultrasonography examinations 
included bilateral whole-breast imaging and were classified into 
one of five final assessments according to the BI-RADS lexicon. 
Category 3 probably benign was defined as a solid mass with oval 
shape, circumscribed margin, parallel orientation, and no suspicious 
malignant features. After ultrasonography, US-CNB was performed 
using a 14-gauge automated core needle and a spring-loaded 
biopsy gun (Promac 2.2L, Manan Medical Products, Northbrook, 
IL, USA). Local anesthesia was routinely applied and at least 5 core 
Fig. 1. Flow chart of the study population. 
US, ultrasound; US-VAE, ultrasound-guided 
vacuum-assisted excision.
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samples were obtained.
Follow-up Ultrasonography
After each biopsy, follow-up ultrasonography was recommended at 
6 months, 12 months, and 24 months. At follow-up ultrasonography, 
a lesion-to-lesion comparison was performed. If a lesion showed 
no change in size and characteristics over 24 months, the final 
assessment was changed to category 2 benign. However, if a 
lesion increased in size in more than 10% of its initial maximal 
diameter or showed any changes in its characteristics on follow-up 
ultrasonography, the lesion was upgraded to category 4 or 5 and 
US-CNB was recommended [10-12].
Surgical Excision or US-guided Vacuum-assisted Excision
Depending on patients’ or physicians’ preference, surgical excision 
or US-guided vacuum-assisted excision (US-VAE) was performed. 
US-VAE using an 8-gauge needle (Mammotome, Ethicon Endo-
Surgery, Cincinnati, OH, USA) was performed as described by Kim et 
al. [13]. To ensure complete mass removal during VAE, we removed 
breast tissue surrounding the lesion at approximately four more 
sampling sites (12, 3, 6, and 9 o’clock directions).
Reference Standards
Among a total of 146 masses, 91 masses underwent surgical 
excision, 35 masses US-VAE, and 20 masses follow-up ultrasono-
graphy. Surgical excision or US-VAE was considered to be the gold 
standard for most lesions. For lesions without changes over two 
years of follow-up ultrasonography, follow-up ultrasonography alone 
was considered to be the gold standard. On the basis of pathologic 
results and follow-up ultrasonography, we calculated the probabilities 
of lesions being benign, borderline and malignant. Borderline 
pathologies included benign or borderline phyllodes tumor.
Statistical Analysis
Statistical analyses were performed using IBM SPSS ver. 19.0 (IBM 
Co., Armark, NY, USA). P<0.05 was considered to indicate statistical 
significance. One-way ANOVA was used to compare age and size on 
follow-up modalities. The independent t-test was used to compare age 
and size on final pathology. The chi-square test was used to compare 
presence of symptoms and diameter changes on final pathology.
Results
All 146 patients in this study were women and 124 patients 
complained of palpable masses. The mean age of the patients 
was 35.7 years, ranging from 13 to 72 years. The mean size of the 
masses was 31.8 cm with a range of 2.0-12 cm.
Correlation with Gold Standards
Among the total 146 masses, surgical excision was done in 91 
Table 1. Clinicopathologic characteristics of the 146 masses in 
146 patients
Variable
Surgical excision 
(n=91)
US-VAE 
(n=35)
Follow-up US 
(n=20)
P-value
Age (yr)  34.9±12.5 33.1±9.9 44.2±13 0.03
Size (mm)  35.5±14.9 24.3±4.5 28.4±9.6 <0.001
Benign 80 (87.9) 30 (85.7) 20 (100) -
Borderline 9 (9.9)   5 (14.3) 0 -
Malignant 2 (2.2) 0 0 -
Values are presented as mean±SD or number (%).
US-VAE, ultrasound-guided vacuum-assisted excision; US, ultrasound.
Fig. 2. A 36-year-old woman with a palpable mass in her left breast.
Transverse (A) and longitudinal (B) ultrasonography reveal a circumscribed, oval, hypoechoic mass in the left lower inner breast. The initial 
diameter of the mass was 20×13×19 mm and the pathologic result of ultrasound-guided core needle biopsy was fibroadenoma. The patient 
underwent surgical excision 82 days later and the result was fibroadenoma.
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masses, US-VAE in 35 masses and follow-up in 20 masses (Table 
1). Patients who underwent surgical excision were older and had 
larger mass size (P<0.05) than other follow-up modalities. The mean 
interval between initial US-CNB and surgical excision or US-VAE 
was 129.7 days (range, 1 to 1,976 days) and 215 days (range, 6 to 
1,621 days), respectively. A total of 20 masses in 20 patients were 
followed with ultrasonography only with a mean follow-up interval 
of 1,664.9 days (range, 897 to 3,027 days). All 20 masses were 
stable or decreased in size after US-CNB over 2 years of follow-up 
ultrasonography.
Finally, 134 patients were diagnosed with benign lesions (Fig. 
2), two patients were diagnosed with malignancies which were all 
malignant phyllodes tumors (Fig. 3), and 10 patients were diagnosed 
with borderline lesions. So, the probabilities of lesions being benign, 
borderline, and malignant were 91.8% (134/146), 6.8% (10/146), 
and 1.4% (2/146), respectively.
Comparison of Benign and Non-Benign Lesions
Table 2 compares the characteristics of the benign and non-benign 
groups. Age, size, and presence of symptoms were not statistically 
different between the benign and non-benign lesions. Among 126 
lesions in which surgical excision and US-VAE were performed, 13 
cases (10.3%) showed the maximal diameter increased by more than 
10% of its initial maximal diameter (Fig. 4). The pathologic results of 
13 growing masses were malignant phyllodes tumor (n=1), benign 
phyllodes tumor (n=2), fibroadenoma (n=5), fibrocystic change (n=2), 
fibroadenomatous hyperplasia (n=2), and sclerosing adenosis (n=1).
Discussion
Ultrasonography has been increasingly used and is an important 
adjunct to mammography in the diagnosis of breast diseases [14]. 
In 2003, ACR developed a BI-RADS ultrasonography lexicon and 
a category 3 probably benign lesion is defined as a solid mass 
with oval shape, circumscribed margin, parallel orientation, and 
no suspicious malignant features [4]. It is not a definite benign 
designation but is expected to be changed infrequently [15].
Several early studies supported the rationale that probably 
benign lesions could be just followed up because of their low risk of 
malignancy (<2%) [10-12,16]. Other recent studies also reported 
similar results which concluded that category 3 probably benign 
lesions should be recommended for follow-up rather than immediate 
Table 2. Clinical characteristics according to the final pathology
Variable
Final pathology
P-value
Benign (n=134) Non-benign (n=12)
Age (yr)  36.2±12.4 30.5±11.2 0.126
Size (mm)  31.6±13.4 34.7±14.2 0.447
Symptomatic 
    patients
114 (85.1) 11 (91.7) 0.533
Increased maximal 
    diameter (D) >10%
10/126 (9.5)
a) 3 (25) -
Values are presented as mean±SD or number (%).
a)126 lesions which underwent surgical excision and ultrasound-guided vacuum-
assisted excision.
Fig. 3. A 28-year-old woman with a mass in her left breast.
Transverse (A) and longitudinal (B) ultrasonography reveal a circumscribed, oval, hypoechoic mass in the left upper outer breast. The initial 
diameter of the mass was 53×26×50 mm and the pathologic result of ultrasound-guided core needle biopsy was fibroadenomatous 
hyperplasia. The patient underwent surgical excision 21 days later and the result was malignant phyllodes tumor.
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biopsy [17-19]. However, further diagnostic imaging work-up should 
be preceded before assessing a lesion as probably benign and 
recommending follow-up [11,20,21]. The first follow-up at 6 months 
is the most important evaluation because rapidly growing cancer 
can be detected without delay [15]. However, less than 2% of 
probably benign lesions are diagnosed as malignancy at this point. 
Leung and Sickles [22] in their cohort study of 1,440 multiple-mass 
cases reported that the interval cancer rate (0.14%) was lower than 
the age-matched United States incident cancer rate (0.24%).
According to the BI-RADS lexicon, a newly detected lesion or an 
enlarged lesion on follow-up mammogram should undergo prompt 
biopsy [4]. Varas et al. [10] reported that when probably benign 
lesions showed an increase in size, loss of distinct borders, increase 
in the number of microcalcifications, new forms of calcifications, 
newly appeared mass within microcalcifications and palpable lumps, 
prompt biopsy was recommended even if it had been previously 
assessed as probably benign. Recently several reports demonstrated 
that probably benign lesions with interval growth should undergo 
biopsy or excision [23-26]. Moon et al. [23] recommended 
prompt biopsy if probably benign lesions showed changes in 
lesion characteristics as well as interval growth on follow-up 
ultrasonography because the malignancy rate increased to 38.5%. 
In our study, a total of 13 masses showed interval growth on follow-
up ultrasonography and one was malignant (7.7%, 1/13). Therefore, 
further study such as surgery, US-VAE or US-CNB is recommended 
when probably benign lesions show interval growth even if initial 
biopsy results are benign.
In this study, surgically confirmed phyllodes tumor were regarded 
as borderline lesions because the management and behavior of 
benign phyllodes are different with fibroadenoma. Phyllodes tumor 
should be treated by wide surgical excision with clear margin 
whereas fibroadenoma is effectively managed by simple enucleation 
[27]. Also it has a tendency to recur, metastasize regardless of 
its histology and malignant potential in some of cases [28,29]. 
Therefore, we considered and analyzed benign phyllodes tumor as 
borderline lesion.
There were several limitations in this study. First, this study was 
a retrospective study with a relatively small number of patients. 
Second, ultrasonography is an operator-dependent process and 
there may be measurement variability among radiologists who 
perform ultrasonography.
In conclusion, US-CNB of probably benign breast lesions with 
benign biopsy results 2 cm or larger was accurate (98.6%) enough 
to rule out malignancy. But, it was difficult to rule out borderline 
lesions even after they were diagnosed as benign through US-CNB.
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Fig. 4. A 42-year-old woman with a palpable mass in her left breast.
A. Transverse ultrasonography reveals a circumscribed, oval, hypoechoic mass in the left upper center breast. The initial diameter of the mass 
was 17×43 mm and the pathologic result of ultrasound-guided core needle biopsy was fibrocystic change. B. Longitudinal ultrasonography 
reveals that the lesion shows an interval increase in diameter, measuring 26×76 mm after 54 months. The patient underwent surgical 
excision and the result was stromal fibrosis and sclerosing adenosis.
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